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HO  position paper on hepatitis A vaccines: June 2012—Recommendations
a  b  s  t  r  a  c  t
This  article  presents  the  World  Health  Organizations  (WHO)  recommendations  onthe  use of  hepatitis  A
vaccineexcerpted  from  the  WHO  position  paper  on  hepatitis  A  vaccines  –  June  2012  recently  published
in  the  Weekly  Epidemiological  Record  [1].  The  current  document  replaces  the  position  paper  on the use
of  hepatitis  A  vaccines  published  in 2000  [2]  and  incorporates  the most  recent  developments  in  the  ﬁeld
with  particular  consideration  to changes  in  the epidemiological  features  of  hepatitis  A infection  in  several
countries,  increased  supply  of hepatitis  A vaccines,  and  new  evidence  on  their  public  health  beneﬁts.
Footnotes  to this  paper  provide  a number  of  core  references  including  references  to  grading  tables  that
assess  the  quality  of  scientiﬁc  evidence  for a few  key  conclusions.
In accordance  with  its mandate  to provide  guidance  to Member  States  on health  policy  matters,
WHO  issues  a series  of regularly  updated  positionpapers  on  vaccines  and  combinations  of  vaccines
against  diseases  that  have  an  international  public  health  impact.  These  papers  are  concerned  primarily
with  the  use  of vaccines  in  large-scale  immunization  programmes;  they  summarize  essential  back-
ground  information  on  diseases  and  vaccines,  and  conclude  with  WHO’s  current  position  on the  use
of  vaccines  in  the global  context.  This  paper  reﬂects  the  recommendations  of WHO’s  Strategic  Advi-
sory  Group  of  Experts  (SAGE)  on  immunization.  These  recommendations  were  discussed  by  SAGE  at
its  November  2011  and  April  2012  meetings.  Evidence  presented  at these  meetings  can  be accessed  at
unizhttp://www.who.int/imm
Both inactivated and live attenuated hepatitis A vaccines are
ighly immunogenic and immunization will generate long-lasting,
ossibly life-long, protection against hepatitis A in children as well
s in adults.
Evidence testiﬁes to the excellent safety proﬁle of inactivated
accines. Although considered safe, internationally published evi-
ence on the safety and tolerability of the live attenuated hepatitis
 vaccines is more limited.
WHO recommends that vaccination against HAV be integrated
nto the national immunization schedule for children aged ≥1 year
f indicated on the basis of incidence of acute hepatitis A, change
n the endemicity from high to intermediate, and consideration of
ost-effectiveness.
Vaccination against hepatitis A should be part of a comprehen-
ive plan for the prevention and control of viral hepatitis, including
easures to improve hygiene and sanitation and measures for out-
reak control.
Countries should collect and review the information needed to
stimate their national burden of hepatitis A. In addition to sur-
eys estimating age-speciﬁc prevalence of anti HAV IgG antibodies,
his may  require examining vital registration systems, acute disease
urveillance, and health information systems capturing fulminant
epatic failure cases and/or causes of liver transplantation. Eco-
omic evaluation, including cost-effectiveness analyses of relevant
mmunization strategies can serve as a useful additional element
or decision-making.
In  highly endemic countries almost all persons are asymptomat-
cally infected with HAV in childhood, which effectively prevents
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clinical  hepatitis A in adolescents and adults. In these countries,
large-scale vaccination programmes are not recommended.
Countries with improving socioeconomic status may  rapidly
move from high to intermediate hepatitis A endemicity. In these
countries, a relatively large proportion of the adult population is
susceptible to HAV and large-scale hepatitis A vaccination is likely
to be cost-effective and is therefore encouraged.
Targeted vaccination of high-risk groups should be considered in
low and very low endemicity settings to provide individual health
beneﬁts. Groups at increased risk of hepatitis A include travellers to
areas of intermediate or high endemicity, those requiring life-long
treatment with blood products, men who have sex with men, work-
ers in contact with non-human primates, and injection drug users.
In addition, patients with chronic liver disease are at increased risk
for fulminant hepatitis A and should be vaccinated.
The use of hepatitis A vaccine rather than passive prophy-
laxis with immune globulin should be considered for pre-exposure
prophylaxis (e.g. for travellers to areas of higher hepatitis A
endemicity) and post-exposure prophylaxis (e.g. for close contacts
of acute cases of hepatitis A).
Recommendations for hepatitis A vaccination in outbreak
situations depend on the epidemiologic features of hepatitis A
in the community and the feasibility of rapidly implementing a
widespread vaccination programme. The use of a single dose reg-
imen of hepatitis A vaccine to control community-wide outbreaks
has been most successful in small self-contained communities,
when vaccination was  started early in the course of the outbreak,
and when high coverage of multiple age-cohorts was achieved.
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accination efforts should be supplemented with health education
nd improved sanitation.
Currently,  inactivated HAV vaccines are licensed for intramus-
ular administration in a 2-dose schedule with the ﬁrst dose given
t the age 1 year, or older. The interval between the ﬁrst (primary)
ose and the second (booster) dose is ﬂexible (from 6 months up to
–5 years), but is usually 6–18 months. The live attenuated vaccine
s administered as a single subcutaneous dose.
National immunization programmes may  consider inclusion
f single-dose inactivated hepatitis A vaccines in immunization
chedules. This option seems to be comparable in terms of effec-
iveness, and is less expensive and easier to implement than the
lassical 2-dose schedule. However, until further experience has
een obtained with a single-dose schedule, in individuals at sub-
tantial risk of contracting hepatitis A, and in immunocompromised
ndividuals, a 2-dose schedule is preferred. Inactivated hepatitis A
accines produced by different manufacturers, including combined
epatitis A vaccines, are interchangeable.
Apart from severe allergic reaction to the previous dose, there iso contraindication to the use of inactivated hepatitis A vaccines.
hese vaccines can be administered simultaneously with any of the
accines routinely used in childhood immunization programmes or
or travel prophylaxis. Inactivated hepatitis A vaccines should also1 (2013) 285– 286
be  considered for use in pregnant women at deﬁnite risk of HAV
infection.
Severe allergy to components included in the live attenuated
hepatitis A vaccines is a contraindication to their use, and as a
rule, live vaccines should not be used in pregnancy or in severely
immunocompromised patients. There is no information available
on co-administration of live attenuated hepatitis A vaccines with
other routinely used vaccines.
Following  introduction, assessment of the impact of hepatitis
A vaccines is important, using information on morbidity and mor-
tality generated by surveillance and study data. Duration of the
protection induced by 1- and 2-dose schedules should be regularly
monitored. In particular, the possible use of a single-dose schedule
should be accompanied by monitoring and evaluation plans.
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